ADVFN - Advanced Financial Network.
HOME» AMEX » P » PLX Stock Price » PLX Stock News

Protalix Biotherapeutics Share News

 Protalix Biotherapeutics, Stock Price
PLX Stock Price
 Protalix Biotherapeutics, Stock Chart
PLX Stock Chart
 Protalix Biotherapeutics, Stock News
PLX Stock News
 Protalix Biotherapeutics, Company Information
PLX Company Information
 Protalix Biotherapeutics, Stock Trades
PLX Stock Trades

CORRECT: FDA Approves Protalix, Pfizer Drug To Treat Gaucher Disease

("FDA Approves Protalix, Pfizer Drug To Treat Gaucher Disease," at 4:36 p.m. EDT, misstated the type of patients in the first paragraph. The correct version follows:) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration Tuesday approved a new treatment developed by Protalix Bio Therapeutics Inc. (PLX, PLX.TV) for adults with a type of Gaucher disease, a rare genetic disorder. The treatment, taliglucerase alfa, will be sold in the U.S. under the brand name Elelyso by Pfizer Inc. (PFE). Pfizer also will sell the drug in most places outside the U.S. The drug, which is the first plant-derived cell-based enzyme replacement, replaces an enzyme called glucocerebrosidase in people with type 1 Gaucher disease. Elelyso is produced using genetically engineered carrot cells. People with Gaucher disease lack glucocerebrosidase, which causes an accumulation of a fatty substance inside cells. The fatty accumulation can lead to enlargement and malfunctioning of the liver, spleen, bone marrow and occasionally, the lung, kidney, and intestine. About 6,000 people in the U.S. have type 1 Gaucher disease according to FDA. Pfizer and Protalix have already been making Elelyso available to some Gaucher disease patients as part of an early access program because of manufacturing issues at Genzyme, a unit of Sanofi (SNY) which makes another glucocerebrosidase-enzyme replacement product, Cerezyme. Earlier this year Genzyme said the manufacturing problems had been fixed and that the company is able to make enough of the product to supply current patients in the U.S. Shire PLC (SHPGY, SHP.LN) which also makes a Gaucher disease treatment, Vpriv, has said inventories of the product will be "below target levels" until the FDA signs off on a second manufacturing plant in the U.S. However, the company also said it has the capacity to meet anticipated demand for Vpriv. Officials from Pfizer and Protalix said the companies have already built enough inventory of Elelyso to supply to patients for at least 24 months. Elelyso is an infusion that is administered by health-care professionals every other week. -By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294;

Stock News for Protalix Biotherapeutics (PLX)
03/12/201516:52:07Annual Report (10-k)
03/12/201516:32:12Current Report Filing (8-k)
02/13/201515:54:14Amended Statement of Ownership (sc 13g/a)
02/12/201507:38:44Current Report Filing (8-k)
02/11/201514:13:50Amended Statement of Ownership (sc 13g/a)
02/02/201507:07:51Current Report Filing (8-k)
01/08/201507:10:55Current Report Filing (8-k)
01/05/201507:07:02Current Report Filing (8-k)
11/17/201416:31:18Initial Statement of Beneficial Ownership (3)
11/12/201407:32:36Current Report Filing (8-k)
11/10/201416:34:00Quarterly Report (10-q)
11/03/201417:06:55Statement of Changes in Beneficial Ownership (4)
11/03/201417:05:13Initial Statement of Beneficial Ownership (3)
10/29/201414:33:41Additional Proxy Soliciting Materials (definitive) (defa14a)
10/09/201416:30:08Proxy Statement (definitive) (def 14a)
10/06/201418:00:25Statement of Changes in Beneficial Ownership (4)
09/29/201417:00:56Proxy Statement - Notice of Shareholders Meeting (preliminary...
09/29/201416:31:14Current Report Filing (8-k)
09/18/201417:59:39Statement of Changes in Beneficial Ownership (4)
09/18/201417:58:30Statement of Changes in Beneficial Ownership (4)

Protalix Biotherapeutics and other American Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations